Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Case report

Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature

Authors: Jie Sun, Xing Wang, Cuifang Wang

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Cystic hypersecretory carcinoma is a rare subtype of breast cancer. It is a member of cystic hypersecretory lesions, which include a series of pathological disease lineages: cystic hypersecretory hyperplasia (CHH), CHH with atypia, cystic hypersecretory carcinoma (CHC) and invasive CHC. It was found that most cystic hypersecretion lesions were in situ carcinoma, and only 19 cases of invasive cystic hypersecretion carcinoma were reported.

Case presentation

We are reporting a case of a 63-year-old female who had a lump in her left breast for 3 years. A modified radical mastectomy was done and morphological diagnosis of invasive CHC with axillary node metastasis was made.

Conclusions

Owing to a smaller number of reported cases, little is known about the biological behavior, prognosis and molecular study of cystic hypersecretion lesions. Therefore, more cases with follow-up data are needed to reveal the biological behavior of this rare tumor.
Literature
1.
Guerry P, Erlandson RA, Rosen PP. Cystic hypersecretory hyperplasia and cystic hypersecretory duct carcinoma of the breast. Cancer. 1988;61:1611–20.CrossRef
2.
Rosen PP, Scott M. Cystic hypersecretory duct carcinoma of the breast. Am J Surg Pathol. 1984;8(1):31–41.CrossRef
3.
Kim MK, Kwon GY, Gong GY. Fine needle aspiration cytology of cystic hypersecretory carcinoma of the breast. A case report. Acta Cytol. 1997;41(3):892–6.CrossRef
4.
Herrmann ME, McClatchey KD, Siziopikou KP. Invasive cystic hypersecretory ductal carcinoma of breast: a case report and review of the literature. Arch Pathol Lab Med. 1999;123(11):1108–10.PubMed
5.
Lee JS, Lee YJ. Invasive cystic hypersecretory carcinoma of the breast: a case report. J Korean Med Sci. 2004;19(1):149–51.CrossRef
6.
Shin SJ, Rosen PP. Carcinoma arising from preexisting pregnancy-like and cystic hypersecretory hyperplasia lesions of the breast: a clinicopathologic study of 9 patients. Am J Surg Pathol. 2004;28(6):789–93.CrossRef
7.
Skalova A, Ryska A, Kajo K, et al. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases. Histopathology. 2005;46(1):43–9.CrossRef
8.
Song SW, Whang IY, Chang ED. Cystic hypersecretory ductal carcinoma of the breast: a rare cause of cystic breast mass. Jpn J Radiol. 2011;29(9):660–2.CrossRef
9.
Bi R, Cheng Y, Yu B, et al. Clinicopathologic features of cystic hypersecretory lesion of the breast. Zhonghua Bing Li Xue Za Zhi. 2014;43(1):25–9.PubMed
10.
Gupta P, Dhingra S, Musa O, et al. Invasive cystic hypersecretory carcinoma of the breast associated with papillary pattern: a rare and poorly recognised variant of ductal carcinoma of the breast. Ecancermedcalscience. 2014;8:477.
11.
Sahoo N, Mishra P, Patra S, et al. Invasive cystic hypersecretory carcinoma of breast: a rare and under diagnosed variant of ductal carcinoma. J Clin Diagn Res. 2017;11(6):ED16–7.PubMedPubMedCentral
12.
Adams GD, Lacey S. Cystic hypersecretory breast carcinoma: an unusual breast cancer. Nebr Med J. 1990;75(5):104–8.PubMed
13.
Chen DB, Kan X. Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case. Zhonghua Bing Li Xue Za Zhi. 2010;39(1):54–5.PubMed
14.
D’Alfonso TM, Ginter PS, Liu YF, et al. Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. Am J Surg Pathol. 2014;38(1):45–53.CrossRef
Metadata
Title
Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature
Authors
Jie Sun
Xing Wang
Cuifang Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5260-2

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-κB pathway activation

Research article

Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas

Research article

Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients

Research article

Clinicopathological characteristics and health care for Tibetan women with breast cancer: a cross-sectional survey

Research article

High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer

Study protocol

SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits